Baiyunshan subsidiary cancels drug manufacturing license amid business pivot

Guangzhou Baiyunshan Star Pearl Pharmaceutical Co., Ltd. (Star Pearl Pharma), a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, has cancelled its "Drug Manufacturing License" (License No. Yue 20160117). This decision follows an announcement from the Guangdong Provincial Medical Products Administration regarding the license's expiration without renewal. The license, which permitted the production of TCM decoction pieces, was valid until September 9, 2025.

Star Pearl Pharma is adjusting its production and operations, focusing its main business on the pre-processing and extraction of traditional Chinese medicine. The company confirmed that its TCM decoction piece business did not generate any operating revenue in 2024.

Guangzhou Baiyunshan Pharmaceutical Holdings stated that this cancellation is part of Star Pearl Pharma's business adjustments and will not impact its ongoing operations or the parent company's current period performance.